JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Corvus Pharmaceuticals Inc

Lezárt

4.36 1.87

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.27

Maximum

4.42

Fő mutatók

By Trading Economics

Bevétel

27M

15M

Munkavállalók

31

EBITDA

-1.8M

-9.9M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+186.08% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

56M

332M

Előző nyitás

2.49

Előző zárás

4.36

Technikai pontszám

By Trading Central

Bizalom

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. aug. 11. 17:49 UTC

Fő piaci mozgatók

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. aug. 11. 17:18 UTC

Fő piaci mozgatók

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. aug. 11. 16:25 UTC

Eredményjelentés

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. aug. 11. 23:50 UTC

Piaci beszéd

Nikkei May Rise as Yen Weakens -- Market Talk

2025. aug. 11. 23:42 UTC

Piaci beszéd

Global Energy Roundup: Market Talk

2025. aug. 11. 23:42 UTC

Piaci beszéd

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. aug. 11. 23:36 UTC

Piaci beszéd

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. aug. 11. 23:32 UTC

Piaci beszéd

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. aug. 11. 23:02 UTC

Piaci beszéd

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. aug. 11. 20:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2025. aug. 11. 20:37 UTC

Eredményjelentés
Felvásárlások, összeolvadások, átvételek

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. aug. 11. 20:37 UTC

Eredményjelentés
Felvásárlások, összeolvadások, átvételek

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. aug. 11. 20:37 UTC

Eredményjelentés
Felvásárlások, összeolvadások, átvételek

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. aug. 11. 20:22 UTC

Eredményjelentés

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. aug. 11. 20:22 UTC

Eredményjelentés

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. aug. 11. 20:22 UTC

Eredményjelentés

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. aug. 11. 20:22 UTC

Eredményjelentés

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. aug. 11. 20:22 UTC

Eredményjelentés

Exodus Movement 2Q Rev $25.8M >EXOD

2025. aug. 11. 20:14 UTC

Piaci beszéd

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. aug. 11. 19:12 UTC

Piaci beszéd

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. aug. 11. 18:56 UTC

Piaci beszéd

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. aug. 11. 18:31 UTC

Piaci beszéd

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. aug. 11. 17:43 UTC

Piaci beszéd

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. aug. 11. 17:28 UTC

Piaci beszéd

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. aug. 11. 17:16 UTC

Piaci beszéd

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. aug. 11. 16:42 UTC

Felvásárlások, összeolvadások, átvételek

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. aug. 11. 16:27 UTC

Felvásárlások, összeolvadások, átvételek

BBVA Says Sabadell Offer Remains in Effect

2025. aug. 11. 16:26 UTC

Felvásárlások, összeolvadások, átvételek

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. aug. 11. 16:25 UTC

Felvásárlások, összeolvadások, átvételek

Banco de Sabadell Announced TSB Sale on July 1

2025. aug. 11. 16:25 UTC

Felvásárlások, összeolvadások, átvételek

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Társak összehasonlítása

Árváltozás

Corvus Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

186.08% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 12.33 USD  186.08%

Magas 15 USD

Alacsony 11 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Corvus Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

4

Vétel

0

Tartás

0

Eladás

Technikai pontszám

By Trading Central

3.165 / 3.5827Támogatás & ellenállás

Rövid táv

Strong Bearish Evidence

Középtáv

Bearish Evidence

Hosszú táv

Weak Bearish Evidence

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.